
1. clin res hepatol gastroenterol. 2015 sep;39(4):443-50. doi:
10.1016/j.clinre.2014.12.007. epub 2015 jan 27.

early virological assessment telaprevir- boceprevir-based triple
therapy hepatitis c cirrhotic patients failed previous interferon based 
regimen - the anrs co20-cupic study.

bailly f(1), virlogeux v(2), dufour c(3), pradat p(1), hézode c(4), larrey d(5), 
alric l(6), samuel d(7), bourlière m(8), métivier s(9), zarski jp(10), fontaine
h(11), loustaud-ratti v(12), serfaty l(13), bronowicki jp(14), carrat f(3),
zoulim f(15); cupic study group.

author information: 
(1)department hepatology, hôpital de la croix-rousse, hospices civils de lyon,
69004 lyon, france; inserm u1052, 69003 lyon, france; université lyon i, 69622
villeurbanne, france.
(2)department hepatology, hôpital de la croix-rousse, hospices civils de lyon,
69004 lyon, france; école normale supérieure, 69007 lyon, france.
(3)inserm umr-s 707, université pierre-et-marie-curie paris 6, 75012 paris,
france.
(4)hépato-gastro-entérologie, chu henri-mondor, 94010 créteil, france.
(5)hépato-gastroentérologie, chu de montpellier, hôpital saint-éloi, 34090
montpellier, france.
(6)pôle digestif, chu purpan, umr 152, université toulouse 3, 31059 toulouse,
france.
(7)centre hépato-biliaire, ap-hp hôpital paul-brousse, 94870 villejuif, france;
unité 785, inserm, 94870 villejuif, france; université paris-sud, 94270 le
kremlin-bicêtre, france.
(8)department hepatology gastroenterology, hôpital saint-joseph, 13285
marseille, france.
(9)pôle digestif-gastro-entérologie-hépatologie, chu purpan, 31059 toulouse,
france.
(10)clinique universitaire d'hépato-gastroentérologie, chru michallon, 38043
grenoble, france.
(11)hôpital cochin, ap-hp, université paris-rené descartes, inserm u1016, 75014
paris, france.
(12)fédération hépatologie, chu dupuytren, 87042 limoges, france.
(13)hépato-gastro-entérologie orienté en hépatologie, chu saint-antoine, 75012
paris, france.
(14)department hepatology gastroenterology, chu de nancy, université de
lorraine, inserm u954, 54500 vandœuvre-lès-nancy, france.
(15)department hepatology, hôpital de la croix-rousse, hospices civils de
lyon, 69004 lyon, france; inserm u1052, 69003 lyon, france; université lyon i,
69622 villeurbanne, france. electronic address: fabien.zoulim@inserm.fr.

background objective: assess within anrs co20-cupic cohort whether the
viral load (vl) week 2/week 6 telaprevir/boceprevir-based triple therapy, 
respectively, predictive sustained virological response (svr) patients 
with hepatitis c virus (hcv) infection study relevance this
measurement early diagnose drug resistance.
methods: observational study hcv genotype 1 patients compensated
cirrhosis (child-pugh a), non-responders prior course interferon
(ifn)-based therapy started triple therapy. patients received either 12
weeks telaprevir combination peg-ifn/ribavirin (rbv), 36 weeks of
peg-ifn/rbv, 4 weeks peg-ifn/rbv, 44 weeks peg-ifn/rbv and
boceprevir.
results: total 262 patients analyzed. telaprevir-treated patients, 
28% undetectable vl w2 81% achieved svr12 whereas 67% had
undetectable vl w4 67% achieved svr12. boceprevir-treated patients
20% undetectable vl w6 86% achieved svr12 whereas 36% had
undetectable vl w8 among 73% achieved svr12. five telaprevir-treated
patients vl increase w2 w4 decrease d0 w2. 
four achieve svr12. similarly, six boceprevir-treated patients
had vl increase w6 w8 decrease d0 w6. five 
not reach svr12.
conclusions: assessment hcv rna level two weeks triple therapy in
cirrhotic non-responder patients good predictor svr. assessment 
useful early diagnosis viral breakthrough.

copyright © 2015 elsevier masson sas. rights reserved.

doi: 10.1016/j.clinre.2014.12.007 
pmid: 25636238  [indexed medline]

